243 related articles for article (PubMed ID: 24435928)
1. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
2. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
Fu W; Tao T; Qi M; Wang L; Hu J; Li X; Xing N; Du R; Han B
Prostate; 2016 Dec; 76(16):1560-1570. PubMed ID: 27527117
[TBL] [Abstract][Full Text] [Related]
4. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.
Wang L; Zhang J; Yang X; Chang YW; Qi M; Zhou Z; Zhang J; Han B
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):301-7. PubMed ID: 23917306
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
6. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4.
Zhang J; Shen C; Wang L; Ma Q; Xia P; Qi M; Yang M; Han B
Biochem Biophys Res Commun; 2014 Sep; 452(3):746-52. PubMed ID: 25201727
[TBL] [Abstract][Full Text] [Related]
7. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
8. SOX4 is activated by C-MYC in prostate cancer.
Dong H; Hu J; Wang L; Qi M; Lu N; Tan X; Yang M; Bai X; Zhan X; Han B
Med Oncol; 2019 Sep; 36(11):92. PubMed ID: 31560094
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
Jin Y; Cui Z; Li X; Jin X; Peng J
Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
[TBL] [Abstract][Full Text] [Related]
10. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
Zhang J; Liang Q; Lei Y; Yao M; Li L; Gao X; Feng J; Zhang Y; Gao H; Liu DX; Lu J; Huang B
Cancer Res; 2012 Sep; 72(17):4597-608. PubMed ID: 22787120
[TBL] [Abstract][Full Text] [Related]
11. SOX4 induces tumor invasion by targeting EMT-related pathway in prostate cancer.
Liu Y; Zeng S; Jiang X; Lai D; Su Z
Tumour Biol; 2017 May; 39(5):1010428317694539. PubMed ID: 28466783
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-19a-3p suppresses invasion and metastasis of prostate cancer via inhibiting SOX4.
Feng YG; Zhao JF; Xiao L; Rao WY; Ran C; Xiao YH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6245-6251. PubMed ID: 30338791
[TBL] [Abstract][Full Text] [Related]
13. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
[TBL] [Abstract][Full Text] [Related]
14. A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis.
Li L; Liu J; Xue H; Li C; Liu Q; Zhou Y; Wang T; Wang H; Qian H; Wen T
Oncogene; 2020 Mar; 39(10):2125-2139. PubMed ID: 31811272
[TBL] [Abstract][Full Text] [Related]
15. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
16. Periostin Mediates TGF-β-Induced Epithelial Mesenchymal Transition in Prostate Cancer Cells.
Hu Q; Tong S; Zhao X; Ding W; Gou Y; Xu K; Sun C; Xia G
Cell Physiol Biochem; 2015; 36(2):799-809. PubMed ID: 26021267
[TBL] [Abstract][Full Text] [Related]
17. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.
Griner NB; Young D; Chaudhary P; Mohamed AA; Huang W; Chen Y; Sreenath T; Dobi A; Petrovics G; Vishwanatha JK; Sesterhenn IA; Srivastava S; Tan SH
Mol Cancer Res; 2015 Feb; 13(2):368-79. PubMed ID: 25344575
[TBL] [Abstract][Full Text] [Related]
18. The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression.
Liu H; Wu Z; Zhou H; Cai W; Li X; Hu J; Gao L; Feng T; Wang L; Peng X; Qi M; Liu L; Han B
Neoplasia; 2019 Aug; 21(8):765-776. PubMed ID: 31238254
[TBL] [Abstract][Full Text] [Related]
19. The effect of microRNA-129 on the migration and invasion in NSCLC cells and its mechanism.
Bin C; Xiaofeng H; Wanzi X
Exp Lung Res; 2018 Aug; 44(6):280-287. PubMed ID: 30475081
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]